BMT Tandem "Scientific" Meeting
Ballroom A-D (Salt Palace Convention Center)
Chairs:
Brett Glotzbecker, MD
and
Ginna G Laport, MD
Summary:
Abstracts: #2539, 2552, 1995, 2711, 2350, 2609
Phase I/II Multicenter Clinical Trial of Lenalidomide Maintenance After Allogeneic Hematopoietic Cell Transplant (alloHCT) in Patients with High Risk (HR) Multiple Myeloma (MM)
Pamela S. Becker, Fred Hutchinson Cancer Research Center;
Melissa Alsina, MD, Moffitt Cancer Center;
Xiaobo Zhong, Medical College of Wisconsin;
Parameswaran N. Hari, MD, MRCP, MS, Medical College of Wisconsin, Hematology/Oncology;
Scott Rowley, MD, Hackensack University Medical Center;
Edward A. Stadtmauer, MD, University of Pennsylvania;
David Vesole, MD, PhD, Hackensack University Medical Center;
Brent R. Logan, PhD, Medical College of Wisconsin;
Daniel J. Weisdorf, MD, University of Minnesota;
Muzaffar Qazilbash, MD, UT MD Anderson Cancer Center;
Leslie Popplewell, MD, FACP, City of Hope National Medical Center;
Willis H. Navarro, MD, University of California, San Francisco;
Marcie Tomblyn, MD, MS, H. Lee Moffitt Cancer Center;
Sergio A. Giralt, MD, Memorial Sloan-Kettering Cancer Center;
Marcelo C. Pasquini, MD, MS, CIBMTR/Medical College of Wisconsin
Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid Irradiation and Anti-Thymocyte Globulin in Lymphoid Malignancies After Failed Autologous Transplantation
Abraham S Kanate, MD, Stanford University;
Bradley Efron, PhD, Stanford University;
Saurabh Chhabra, MD, Stanford University;
Holbrook Kohrt, MD, Stanford University;
Judith A. Shizuru, MD, PhD, Stanford University Medical Center;
Ginna G Laport, MD, Stanford University Medical Center;
David B. Miklos, MD, PhD, Stanford University Medical Center;
Jonathan Benjamin, MD, PhD, Stanford University;
Laura Johnston, MD, Stanford University;
Sally Arai, MD, Stanford University;
Wen-Kai Weng, MD, Stanford University;
Robert Negrin, MD, Stanford University;
Samuel Strober, MD, Stanford University Medical Center;
Robert Lowsky, MD, Stanford University
Remission Duration ≤ 12 Months for Early Relapsed and Refractory Follicular Lymphoma Is Predictive of Early Failures Post-High Dose Therapy and Autologous Stem Cell Rescue
Matthew Alexander Lunning, D.O., Memorial Sloan-Kettering Cancer Center;
Jocelyn Maragulia, MS, Memorial Sloan-Kettering Cancer Center;
Craig H. Moskowitz, MD, Memorial Sloan-Kettering Cancer Center;
Hugo Castro-Malaspina, M.D., Memorial Sloan-Kettering Cancer Center;
Sergio A. Giralt, MD, Memorial Sloan-Kettering Cancer Center;
Andrew D Zelenetz, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center;
Craig Steven Sauter, MD, Memorial Sloan-Kettering Cancer Center
Suppression of Involved Immunoglobulin Free Light Chain Post Therapy and Survival Outcomes Following Autologous Stem Cell Transplantation for Myeloma
Jacob Smeltzer, Mayo Clinic;
Morie Gertz, MD, Mayo Clinic;
S. Vincent Rajkumar, Mayo Clinic;
Angeal Dispenzieri, Mayo Clinic;
Martha Lacy, MD, Mayo Clinic;
Francis Buadi, MD, Mayo Clinic;
Suzanne Hayman, MD, Mayo Clinic;
David Dingli, Mayo Clinic;
Prashant Kapoor, Mayo Clinic;
Shaji Kumar, MD, Mayo Clinic
CT7/MAGE-C1 Expression and Immune Responses Following Allogeneic Transplant for Multiple Myeloma
Eleanor M. Tyler, Sloan-Kettering Institute;
Achim A. Jungbluth, MD, Ludwig Institute for Cancer Research, New York Branch;
Sacha Gnjatic, PhD, Ludwig Institute for Cancer Research, New York Branch;
Richard O'Reilly, MD, Memorial Sloan-Kettering Cancer Center;
Guenther Koehne, MD, PhD, Memorial Sloan-Kettering Cancer Center
![[Visit Client Website]](images/banner.gif)